Hot Features
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that i... Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1 | -8 | 1.25 | 1.275 | 1.14 | 792018 | 1.1844304 | CS |
| 4 | -0.1 | -8 | 1.25 | 1.275 | 1.13 | 539832 | 1.19176999 | CS |
| 12 | -0.26 | -18.4397163121 | 1.41 | 1.435 | 1.13 | 526170 | 1.24845052 | CS |
| 26 | -0.18 | -13.5338345865 | 1.33 | 1.435 | 1.09 | 737824 | 1.24993809 | CS |
| 52 | -0.5 | -30.303030303 | 1.65 | 1.95 | 1.09 | 922425 | 1.39704387 | CS |
| 156 | -21.02 | -94.8128101037 | 22.17 | 24.74 | 1.09 | 859724 | 6.41113911 | CS |
| 260 | -29.65 | -96.2662337662 | 30.8 | 36.64 | 1.09 | 744136 | 11.19597089 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.